lipid-a and Pneumonia--Pneumococcal

Alternative treatment strategies against bacterial infections are required to decrease the use of antibiotics. This study tested the hypothesis that stimulation of the innate immune receptor Toll-like receptor 4 can be combined with antibiotics to improve the treatment of invasive pneumonia. The efficacy of the biosynthetic monophosphoryl lipid A (MPLA), a clinically approved Toll-like receptor 4 activator, was tested in a mouse model of

Topics: Animals; Anti-Bacterial Agents; Lipid A; Mice; Pneumonia, Pneumococcal; Treatment Outcome